Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses

Comments
Loading...
Zinger Key Points

The U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi SA’s SNY Genzyme Corporation regarding significant violations at its Framingham, Massachusetts, facility.

After an inspection conducted between June 12 and July 9, 2024 the agency flagged major concerns about the facility’s processes for producing active pharmaceutical ingredients, or APIs.

Also Read: Sanofi’s Blood Cancer Drug’s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma

Inspection Findings

  • FDA investigators documented several critical issues, including a failure to adequately investigate deviations, address manufacturing inconsistencies, and use properly designed equipment.
  • Approximately 20% of bioreactor runs between January 2022 and July 2024 were rejected due to contamination or other quality failures, highlighting serious process control deficiencies.
  • Investigations into these incidents often lacked thorough root cause analyses, appropriate corrective actions, or adequate documentation.
  • For example, two lots of APIs were found to contain visible particles, but investigations failed to address all contributing factors. Additionally, high-pressure product leakage events during manufacturing were inadequately reviewed, and engineering study conclusions were ignored.
  • The FDA noted instances where Genzyme deviated from validated manufacturing processes, increasing the risk of microbial contamination.
  • One notable deviation involved the unauthorized substitution of manufacturing components, which was later linked to contamination events.
  • The agency also criticized using unsuitable equipment, including mobile carts and devices with known design flaws that could allow microbial ingress.

The facility’s quality unit was also scrutinized for its inability to ensure compliance with current Good Manufacturing Practices standards. As of June 2024, the quality unit had 84 open and overdue deviation investigations, some exceeding 180 days. FDA inspectors observed unreported deviations, such as improper aseptic practices and equipment setup issues.

The FDA also found Genzyme’s proposed corrective and preventive actions (CAPAs) insufficient.

Sanofi must respond within 15 working days, outlining its corrective measures and provide the FDA with a timeline for completion.

Price Action: Sanofi stock is down 0.91% at $51.22 at last check Wednesay.

Read Next:

Image: Shutterstock

SNY Logo
SNYSanofi SA
$52.781.80%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
72.11
Growth
29.30
Quality
71.48
Value
50.13
Price Trend
Short
Medium
Long
Got Questions? Ask
How will Sanofi address FDA's concerns?
Which pharmaceutical companies may face scrutiny next?
What impact on biotech stocks due to FDA actions?
Could contract manufacturers gain from Sanofi's issues?
Which investment funds focus on biopharma compliance?
How might quality control technologies see increased demand?
Will Sanofi's issues affect generic drug producers?
What alternatives exist for investors in pharmaceuticals?
How do regulatory changes impact biotech investments?
Could Sanofi's stock rebound after compliance issues?

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

Posted In: